Published

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Psychedelic medicine (New Rochelle, N.Y.)
Date: 2026-09-01
Source: PubMed
DOI: 10.1177/28314425251404460
PubMed: 42539893

Authors

Back AL McGregor BA Billingsley L Blom D Callan G Myers S Guy J Kumar S Layer M Levin J Perez J Thompson P Salmonson K Whinney J Thorn LL

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Emotional Processing Clinical Trial Cancer Patients Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.2026-09-01 A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience2026-04-14

Related papers

Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.ClinicalTrials.gov · 2025-11-19 Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot StudyClinicalTrials.gov · 2026-03-18 Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.Expert opinion on drug safety · 2022-06-01 Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling.Therapeutic advances in drug safety · 2026-01-01 Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.Drug safety · 2025-05-01 [Discrimination of psychoactive fungi (commonly called "magic mushrooms") based on the DNA sequence of the internal transcribed spacer region].Shokuhin eiseigaku zasshi. Journal of the Food Hygienic Society of Japan · 2003-02-01 Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin CompoundsACS Omega · 2025-09-30 Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents.Expert opinion on drug safety · 2023-01-01